Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. Tyrosine kinase inhibitors (TKIs) remain the backbone of systematic therapy for advanced hepatocellular carcinoma. Sorafenib and lenvatinib are currently approved as first-line therapeutic drugs, and regorafenib an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ruyin, Li, Qiong, Xu, Shuaishuai, Ye, Chanqi, Tian, Tian, Jiang, Qi, Shan, Jianzhen, Ruan, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840552/
https://www.ncbi.nlm.nih.gov/pubmed/35148789
http://dx.doi.org/10.1186/s12935-021-02435-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840552/
https://www.ncbi.nlm.nih.gov/pubmed/35148789
http://dx.doi.org/10.1186/s12935-021-02435-4

Ejemplares similares